Ligand Pharmaceuticals Incorporated Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:LGND
  • CUSIP: 53220K50
  • Web: www.ligand.com
Capitalization:
  • Market Cap: $2.87 billion
  • Outstanding Shares: 21,053,000
Average Prices:
  • 50 Day Moving Avg: $128.78
  • 200 Day Moving Avg: $116.74
  • 52 Week Range: $87.50 - $138.49
P/E:
  • Trailing P/E Ratio: 332.15
  • Foreward P/E Ratio: 35.33
  • P/E Growth: 1.44
Sales & Book Value:
  • Annual Revenue: $117.07 million
  • Price / Sales: 24.53
  • Book Value: $19.45 per share
  • Price / Book: 7.01
Profitability:
  • EBIDTA: $60.55 million
  • Net Margins: 7.39%
  • Return on Equity: 5.05%
  • Return on Assets: 2.94%
Debt:
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 0.87%
  • Quick Ratio: 0.84%
Misc:
  • Average Volume: 251,136 shs.
  • Beta: 0.99
  • Short Ratio: 28.6
 

Frequently Asked Questions for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

What is Ligand Pharmaceuticals Incorporated's stock symbol?

Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals Incorporated's earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced its quarterly earnings data on Monday, August, 7th. The company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.42. The company earned $28 million during the quarter, compared to the consensus estimate of $24.40 million. Ligand Pharmaceuticals Incorporated had a net margin of 7.39% and a return on equity of 5.05%. The company's quarterly revenue was up 43.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.50 EPS. View Ligand Pharmaceuticals Incorporated's Earnings History.

When will Ligand Pharmaceuticals Incorporated make its next earnings announcement?

Ligand Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Ligand Pharmaceuticals Incorporated.

Where is Ligand Pharmaceuticals Incorporated's stock going? Where will Ligand Pharmaceuticals Incorporated's stock price be in 2017?

5 analysts have issued 1 year price targets for Ligand Pharmaceuticals Incorporated's shares. Their predictions range from $104.00 to $160.00. On average, they expect Ligand Pharmaceuticals Incorporated's share price to reach $135.17 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.

What are analysts saying about Ligand Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals Incorporated stock:

  • 1. HC Wainwright analysts commented, "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" (9/5/2017)
  • 2. According to Zacks Investment Research, "Ligand’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. However, the company derives a substantial portion of its revenues from royalties associated with the sales of two products – Promacta and Kyprolis. Any setback related to either of these two products could have a substantial impact on the company’s results. Notably, Ligand obtains Captisol from a single supplier. Hence any interruption in the supply of Captisol would have an adverse effect on the company’s results. Shares of Ligand have outperformed the broader industry in the last one year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/11/2017)

Who are some of Ligand Pharmaceuticals Incorporated's key competitors?

Who are Ligand Pharmaceuticals Incorporated's key executives?

Ligand Pharmaceuticals Incorporated's management team includes the folowing people:

  • Matthew W. Foehr, President, Chief Operating Officer
  • John L. Higgins, Chief Executive Officer, Director
  • Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
  • Charles S. Berkman J.D., Vice President, General Counsel, Secretary
  • John W. Kozarich, Non-Executive Independent Chairman of the Board
  • Nancy Ryan Gray, Director
  • Jason M. Aryeh, Independent Director
  • Todd C. Davis, Independent Director
  • John L. LaMattina Ph.D., Independent Director

Who owns Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.78%), William Blair Investment Management LLC (8.45%), Vanguard Group Inc. (8.30%), State Street Corp (3.86%), Victory Capital Management Inc. (3.23%) and Janus Henderson Group PLC (2.83%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.

Who sold Ligand Pharmaceuticals Incorporated stock? Who is selling Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including AJO LP, State of New Jersey Common Pension Fund D, State Street Corp, FMR LLC, Elk Creek Partners LLC, Columbia Partners L L C Investment Management, Principal Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Ligand Pharmaceuticals Incorporated stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

Who bought Ligand Pharmaceuticals Incorporated stock? Who is buying Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Macquarie Group Ltd., Castleark Management LLC, Royal Bank of Canada, BlackRock Inc., Rice Hall James & Associates LLC and Tygh Capital Management Inc.. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

How do I buy Ligand Pharmaceuticals Incorporated stock?

Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals Incorporated's stock price today?

One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $136.38.


MarketBeat Community Rating for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $135.17 (0.89% downside)

Analysts' Ratings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017HC WainwrightReiterated RatingBuy -> Buy$150.00MediumView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 -> $137.00LowView Rating Details
8/8/2017Deutsche Bank AGBoost Price TargetHold$103.00 -> $104.00HighView Rating Details
8/8/2017Roth CapitalBoost Price TargetBuy$120.00 -> $135.00HighView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
10/5/2016Craig HallumBoost Price Target$150.00 -> $160.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Earnings by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Earnings History by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017        
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.43$0.43$0.43
Q2 20171$0.60$0.60$0.60
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.00View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.00View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.72View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.20View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.81View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.00View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Latest Headlines for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Source:
DateHeadline
finance.yahoo.com logoGlaxo's Shingles Candidate Gets Positive FDA Committee Vote
finance.yahoo.com - September 15 at 5:41 AM
finance.yahoo.com logoPfizer Lung Cancer Drug's Overall Survival Data Unfavorable
finance.yahoo.com - September 14 at 7:08 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Expected to Announce Quarterly Sales of $31.22 Million
www.americanbankingnews.com - September 13 at 3:14 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 12 at 9:03 AM
nasdaq.com logo5 Top-Ranked Biotech Stocks to Buy Right Now - Nasdaq
www.nasdaq.com - September 12 at 3:24 AM
nasdaq.com logoLigand (LGND) Up 9.6% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - September 8 at 1:17 AM
finance.yahoo.com logoLigand (LGND) Up 9.6% Since Earnings Report: Can It Continue?
finance.yahoo.com - September 8 at 1:17 AM
streetinsider.com logoLigand Pharma (LGND) Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes Achieves Statistical Significance
www.streetinsider.com - September 7 at 2:42 AM
finance.yahoo.com logoLigand (LGND) Diabetes Candidate Positive in Phase II Study
finance.yahoo.com - September 7 at 2:42 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,000 Shares
www.americanbankingnews.com - September 6 at 10:26 PM
nasdaq.com logoLigand (LGND) Diabetes Candidate Positive in Phase II Study - Nasdaq
www.nasdaq.com - September 6 at 9:38 PM
finance.yahoo.com logoBrexanolone Could Strengthen Ligand’s Neurology Portfolio
finance.yahoo.com - September 6 at 9:37 PM
finance.yahoo.com logoCaptisol-Enabled Prexasertib May Be Major Growth Driver for Ligand
finance.yahoo.com - September 6 at 9:37 PM
businesswire.com logoLigand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes - Business Wire (press release)
www.businesswire.com - September 6 at 1:59 AM
streetinsider.com logoLigand Pharma (LGND) Phase 2 Study of LGD-6972 in Patients with ... - StreetInsider.com
www.streetinsider.com - September 5 at 3:57 PM
finance.yahoo.com logoLigand Announces Top-Line Results from Phase 2 Study of LGD-6972 in Patients with Type 2 Diabetes
finance.yahoo.com - September 5 at 3:57 PM
finance.yahoo.com logoAnalyst Makes The Case For Ligand As A 'Core' Holding
finance.yahoo.com - September 5 at 3:57 PM
finance.yahoo.com logo4 Biotech Stocks to Improve Your Portfolio's Health
finance.yahoo.com - September 5 at 3:57 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Research Coverage Started at HC Wainwright
www.americanbankingnews.com - September 5 at 8:38 AM
finance.yahoo.com logoLigand Pharmaceuticals’ Shots-on-Goal Business Model
finance.yahoo.com - September 1 at 2:24 AM
finance.yahoo.com logoFully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals
finance.yahoo.com - September 1 at 2:24 AM
finance.yahoo.com logo3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock
finance.yahoo.com - August 30 at 5:52 AM
americanbankingnews.com logo$29.36 Million in Sales Expected for Ligand Pharmaceuticals Incorporated (LGND) This Quarter
www.americanbankingnews.com - August 26 at 9:26 PM
americanbankingnews.com logoJason Aryeh Sells 2,000 Shares of Ligand Pharmaceuticals Inc. (LGND) Stock
www.americanbankingnews.com - August 25 at 8:10 PM
seekingalpha.com logoLigand: Situated For Growth - Seeking Alpha
seekingalpha.com - August 22 at 8:35 PM
nasdaq.com logo4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings - Nasdaq
www.nasdaq.com - August 22 at 3:23 PM
finance.yahoo.com logo4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings
finance.yahoo.com - August 22 at 3:23 PM
streetinsider.com logoLigand Pharma (LGND) Names Dr. Nancy Gray to Board
www.streetinsider.com - August 22 at 5:37 AM
streetinsider.com logoLigand Pharma (LGND) Names Dr. Nancy Gray to Board - StreetInsider.com
www.streetinsider.com - August 21 at 7:35 PM
finance.yahoo.com logoLigand Appoints Dr. Nancy Gray to its Board of Directors
finance.yahoo.com - August 21 at 7:35 PM
streetinsider.com logoLigand Pharma (LGND) Receive $2M from WuXi Biologics for Licensing anti-PD-1 Antibody Discovered Using the ... - StreetInsider.com
www.streetinsider.com - August 20 at 10:45 AM
streetinsider.com logoLigand Pharma (LGND) Receive $2M from WuXi Biologics for Licensing anti-PD-1 Antibody Discovered Using the OmniAb Technology
www.streetinsider.com - August 18 at 8:30 PM
finance.yahoo.com logoStrength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%
finance.yahoo.com - August 18 at 8:29 PM
finance.yahoo.com logoLigand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage anti-PD-1 Antibody Discovered Using the OmniAb® Technology
finance.yahoo.com - August 18 at 8:29 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 18 at 8:38 AM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.
finance.yahoo.com - August 12 at 2:31 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Insider Matthew W. Foehr Sells 6,100 Shares
www.americanbankingnews.com - August 10 at 7:48 PM
americanbankingnews.com logoInsider Selling: Ligand Pharmaceuticals Incorporated (LGND) CEO Sells 5,483 Shares of Stock
www.americanbankingnews.com - August 10 at 7:48 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) VP Sells $2,364,630.00 in Stock
www.americanbankingnews.com - August 10 at 7:26 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (LGND) Raised to "B-" at TheStreet
www.americanbankingnews.com - August 9 at 9:10 AM
finance.yahoo.com logoEdited Transcript of LGND earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 1:17 AM
seekingalpha.com logoLigand Pharmaceuticals' (LGND) CEO John Higgins on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 8:16 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Price Target Raised to $104.00 at Deutsche Bank AG
www.americanbankingnews.com - August 8 at 11:10 AM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Price Target Raised to $135.00 at Roth Capital
www.americanbankingnews.com - August 8 at 9:32 AM
businesswire.com logoLigand Reports Second Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - August 7 at 8:49 PM
finance.yahoo.com logoLigand Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 8:49 PM
finance.yahoo.com logoLigand posts 2Q profit
finance.yahoo.com - August 7 at 8:49 PM
americanbankingnews.com logoLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Posts Quarterly Earnings Results, Beats Expectations By $0.21 EPS
www.americanbankingnews.com - August 7 at 5:14 PM
americanbankingnews.com logo Analysts Expect Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to Post $0.25 EPS
www.americanbankingnews.com - August 5 at 10:38 PM
seekingalpha.com logoLigand Pharmaceuticals: A Good Long-Term Investment - Seeking Alpha
seekingalpha.com - August 5 at 1:26 AM

Social

Chart

Ligand Pharmaceuticals Incorporated (LGND) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff